Subtype
Urinary Tract Carcinoma
CI-CAN-00007014Explore in graph →
327 active trials11 approved drugs23 evidence items
- NCIt
- C192669
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00007014Explore in graph →
Clinical trials
853 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (127)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05097404 | Clinical Utility of VI-RADS in Diagnosis of MIBC | unknown | — | 73 | Samsung Medical CenterOTHER | 1 | Oct 28, 2021 | clinicaltrials |
| NCT05086666 | A Phase 1b/2 Clinical Study to Evaluate the Safety and Tolerability and Efficacy of AZD4547 | unknown | Phase 1 / Phase 2 | 108 | Abbisko Therapeutics Co, LtdINDUSTRY | 1 | Oct 21, 2021 | clinicaltrials |
| NCT03091764 |
| Evaluation of a Patient-Reported Symptom Index for NMIBC |
| completed |
| — |
| 498 |
| University of SydneyOTHER |
| 5 |
| Oct 13, 2021 |
| clinicaltrials |
| NCT03115801 | A Phase II Randomized Trial of Immunotherapy Plus Radiotherapy in Metastatic Genitourinary Cancers | terminated | Phase 2 | 6 | Weill Medical College of Cornell UniversityOTHER | 1 | Sep 22, 2021 | clinicaltrials |
| NCT04432909 | A Prospective, Multi-centre, Single-blinded Study of UroCAD for Urothelial Carcinoma Diagnosis and Follow-up | unknown | — | 500 | Changhai HospitalOTHER | 1 | Sep 16, 2021 | clinicaltrials |
| NCT05043662 | UroCAD Assay Combined With Computed Tomography Urography and Urine Cytology for UTUC Diagnosis. | unknown | — | 110 | Changhai HospitalOTHER | 1 | Sep 14, 2021 | clinicaltrials |
| NCT05030077 | Anlotinib Combined With Platinum/Gemcitabine for First Line Treatment of Advanced Urothelial Carcinoma | unknown | Phase 2 | 53 | Tianjin Medical University Second HospitalOTHER | 1 | Sep 1, 2021 | clinicaltrials |
| NCT04066595 | Cabozantinib in Patients With Locally Advanced or Metastatic Urothelial Cell Carcinoma.(CabUC) | terminated | Phase 2 | 7 | Johannes Gutenberg University MainzOTHER | 1 | Aug 30, 2021 | clinicaltrials |
| NCT05027412 | En Bloc TURBT With Collins Loop vs Conventional TURBT(TURBT) | unknown | N/A | 80 | Hospital Universitario de FuenlabradaOTHER | 1 | Aug 30, 2021 | clinicaltrials |
| NCT04815629 | Outcome of Radiation Therapy in Urinary Bladder Squampus Cell Carcinoma | unknown | — | 40 | Assiut UniversityOTHER | 0 | Aug 18, 2021 | clinicaltrials |
| NCT04871334 | Safety, Tolerability and Pharmacokinetics of TWP-101 in Patients With Advanced Melanoma and Urothelial Carcinoma | unknown | Phase 1 | 76 | Shandong TheraWisdom Biopharma Co., Ltd.INDUSTRY | 1 | Jul 23, 2021 | clinicaltrials |
| NCT04966130 | Effect of Urinary Indwelling Time on Early Continence After Robot-assisted Radical Cystectomy With Orthotopic Ileal Neobladder. | unknown | — | 96 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 0 | Jul 19, 2021 | clinicaltrials |
| NCT04579133 | Neoadjuvant Durvalumab Alone Versus Durvalumab With Olaparib in Patients Ineligible for Cisplatin With Muscle-Invasive Urothelial Carcinoma of the Bladder Followed by Radical Cystectomy | terminated | Phase 2 | 140 | Latin American Cooperative Oncology GroupOTHER | 1 | Jun 16, 2021 | clinicaltrials |
| NCT00118040 | Phase II Study of Isoflavone G-2535 (Genistein) in Patients With Bladder Cancer | completed | Phase 2 | 60 | National Cancer Institute (NCI)NIH | 1 | Jun 10, 2021 | clinicaltrials |
| NCT02009332 | Phase 1/2 Study of ABI-009 in Nonmuscle Invasive Bladder Cancer | completed | Phase 1 / Phase 2 | 21 | Aadi Bioscience, Inc.INDUSTRY | 1 | Jun 8, 2021 | clinicaltrials |
| NCT04909775 | Chemotherapy Combined With Tislelizumab as Bladder Sparing Option for Patients With Muscle Invasive Bladder Cancer | unknown | Phase 2 | 40 | Ruijin HospitalOTHER | 1 | Jun 2, 2021 | clinicaltrials |
| NCT04900558 | Robotic Radical Cystectomy Outcomes | recruiting | — | 500 | University of FlorenceOTHER | 1 | May 25, 2021 | clinicaltrials |
| NCT02693717 | Pemetrexed Disodium in Treating Patients With Previously Treated Metastatic Urothelial Cancer | terminated | Phase 2 | 7 | M.D. Anderson Cancer CenterOTHER | 1 | May 20, 2021 | clinicaltrials |
| NCT02818725 | I-MVAC +/- Panitumumab as First-line Treatment of Advanced Urothelial Carcinoma Without H-Ras Nor K-Ras Mutations(GETUG-AFU19) | completed | Phase 3 | 133 | UNICANCEROTHER | 1 | Mar 9, 2021 | clinicaltrials |
| NCT03125226 | TracelT Hydrogel in Localizing Bladder Tumors in Patients Undergoing Radiation Therapy for Bladder Cancer | completed | N/A | 12 | University of WashingtonOTHER | 1 | Feb 25, 2021 | clinicaltrials |
| NCT03824691 | hARnessing CAbozantinib and Durvalumab Immuno-oncology Association: ARCADIA Study"(ARCADIA) | unknown | Phase 2 | 122 | Fondazione IRCCS Istituto Nazionale dei Tumori, MilanoOTHER | 1 | Feb 25, 2021 | clinicaltrials |
| NCT04383067 | A Phase 2, Single-Center, Open Label Study of Autologous, Adoptive Cell Therapy Following a Reduced Intensity, Non-myeloablative, Lymphodepleting Induction Regimen in Metastatic Urothelial Carcinoma Patients | unknown | Phase 2 | 20 | Sheba Medical CenterOTHER_GOV | 1 | Feb 11, 2021 | clinicaltrials |
| NCT04647981 | Diagnostic Performance Evaluation Study of the Xpert® Bladder Cancer Monitor Test.(Xpert Bladder) | completed | — | 320 | Clinique Beau SoleilOTHER | 1 | Feb 9, 2021 | clinicaltrials |
| NCT04686149 | a Genome-based Platform to Predict Patients That Can Achieve Bladder Preservation in Muscle Invasive Bladder Cancer Patients | unknown | — | 39 | Yonsei UniversityOTHER | 1 | Dec 28, 2020 | clinicaltrials |
| NCT02793128 | The OLYMPUS Study - Optimized DeLivery of Mitomycin for Primary UTUC Study(Olympus) | completed | Phase 3 | 71 | UroGen Pharma Ltd.INDUSTRY | 2 | Dec 22, 2020 | clinicaltrials |
| NCT04211012 | A Study on Toripalimab Plus Nab-Paclitaxel With or Without Cisplatin as First-line Treatment of Urothelial Carcinoma | unknown | Phase 2 | 30 | Jun GuoOTHER | 1 | Nov 13, 2020 | clinicaltrials |
| NCT02788201 | Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma | completed | Phase 2 | 8 | National Cancer Institute (NCI)NIH | 1 | Nov 6, 2020 | clinicaltrials |
| NCT03538028 | A Safety and Tolerability Study of INCAGN02385 in Select Advanced Malignancies | completed | Phase 1 | 22 | Incyte Biosciences International SàrlINDUSTRY | 1 | Oct 30, 2020 | clinicaltrials |
| NCT00478361 | Gemcitabine, Paclitaxel, Doxorubicin in Metastatic or Unresectable Bladder Cancer With Decreased Kidney Function | completed | Phase 2 | 40 | M.D. Anderson Cancer CenterOTHER | 1 | Oct 9, 2020 | clinicaltrials |
| NCT03113266 | Safety and Efficacy of Toripalimab for Patients With Locally Advanced or Metastatic Bladder Urothelial Carcinoma | unknown | Phase 2 | 370 | Shanghai Junshi Bioscience Co., Ltd.OTHER | 1 | Sep 30, 2020 | clinicaltrials |
| NCT03794128 | A Study of Personalized Neoantigen Cancer Vaccines | completed | — | 93 | Gritstone bio, Inc.INDUSTRY | 1 | Sep 11, 2020 | clinicaltrials |
| NCT00749892 | Erlotinib Hydrochloride in Treating Participants With Muscle Invasive or Recurrent Urothelial Cancer | completed | Phase 2 | 34 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 10, 2020 | clinicaltrials |
| NCT03719300 | Codex: Study of Inodiftagene Vixteplasmid (BC-819) in Unresponsive NMIBC | terminated | Phase 2 | 32 | Anchiano Therapeutics Israel Ltd.INDUSTRY | 1 | Aug 19, 2020 | clinicaltrials |
| NCT03167151 | Pembrolizumab in Intermediate Risk Recurrent Non-muscle Invasive Bladder Cancer (NMIBC)(PemBla) | terminated | Phase 1 / Phase 2 | 6 | University of OxfordOTHER | 1 | Jul 31, 2020 | clinicaltrials |
| NCT02688348 | Quality of Life After Bladder-Preservation Chemotherapy and Radiation Therapy in Patients With Muscle-Invasive Bladder Cancer | withdrawn | N/A | 0 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Jul 24, 2020 | clinicaltrials |
| NCT03672240 | Study of APL-1202 in Non-Muscle Invasive Bladder Cancer Patients Who Are Resistant to One Induction Course of BCG Treatment(NMIBC) | completed | Phase 1 / Phase 2 | 6 | Asieris Pharmaceutical Technologies Co., Ltd.INDUSTRY | 1 | Jul 20, 2020 | clinicaltrials |
| NCT03407976 | Apatinib With Pembrolizumab in Previously Treated Advanced Malignancies(APPEASE) | terminated | Phase 1 | 5 | University of UtahOTHER | 1 | Jul 15, 2020 | clinicaltrials |
| NCT02169284 | Erlotinib Hydrochloride in Treating Patients With Bladder Cancer Undergoing Surgery | terminated | Phase 2 | 50 | National Cancer Institute (NCI)NIH | 1 | Jul 7, 2020 | clinicaltrials |
| NCT03517995 | Randomized, Phase II Clinical Trial of Sulforaphane in Bladder Cancer Chemoprevention | withdrawn | Phase 2 | 0 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | May 28, 2020 | clinicaltrials |
| NCT01993979 | A Phase III Randomised Trial of Peri-Operative Chemotherapy Versus sUrveillance in Upper Tract Urothelial Cancer (POUT)(POUT) | unknown | Phase 3 | 261 | Institute of Cancer Research, United KingdomOTHER | 1 | May 4, 2020 | clinicaltrials |
| NCT03335059 | Mitomycin C Intravesical Chemotherapy in Conjunction With Synergo® Radiofrequency-Induced Hyperthermia for Treatment of Carcinoma in Situ Non-Muscle Invasive Bladder Cancer Patients Unresponsive to Bacillus Calmette-Guérin, With or Without Papillary Tumors.(RITE-USA) | terminated | Phase 3 | 5 | Medical Enterprises Ltd.INDUSTRY | 1 | Apr 15, 2020 | clinicaltrials |
| NCT04295967 | Vasculogenic Mimicry in Urothelial Carcinoma | unknown | — | 70 | Assiut UniversityOTHER | 0 | Mar 5, 2020 | clinicaltrials |
| NCT02700659 | The Cxbladder Monitoring Study | completed | — | 803 | Pacific Edge LimitedINDUSTRY | 1 | Mar 4, 2020 | clinicaltrials |
| NCT04264936 | A Study of RC48-ADC(Antibody Drug Conjugate) and JS001 to Evaluate the Safety and Pharmacokinetics of Subjects With Locally Advanced or Metastatic Urothelial Cancer | unknown | Phase 1 / Phase 2 | 36 | Peking University Cancer Hospital & InstituteOTHER | 1 | Feb 13, 2020 | clinicaltrials |
| NCT03159585 | To Evaluate the Efficacy of NY-ESO-1-specific T Cell Receptor Affinity Enhancing Specific T Cell in Solid Tumors | completed | Phase 1 | 6 | Zhujiang HospitalOTHER | 1 | Jan 22, 2020 | clinicaltrials |
| NCT04223063 | Exercise-based Pre-habilitation in Bladder Cancer Patients Prior to Radical Cystectomy: a Feasibility Study | unknown | N/A | 20 | Ross MasonOTHER | 0 | Jan 10, 2020 | clinicaltrials |
| NCT03935347 | Adoptive Cell Therapy With (LN-145) in Combination With Pembrolizumab in Treating Patients With Unresectable or Metastatic Transitional Cell Cancer Who Have Failed Cisplatin-Based Chemotherapy | withdrawn | Phase 2 | 0 | Roswell Park Cancer InstituteOTHER | 1 | Jan 2, 2020 | clinicaltrials |
| NCT02178241 | Gemcitabine Hydrochloride and Eribulin Mesylate in Treating Patients With Bladder Cancer That is Advanced or Cannot Be Removed by Surgery | completed | Phase 2 | 26 | National Cancer Institute (NCI)NIH | 2 | Dec 16, 2019 | clinicaltrials |
| NCT04129606 | Bladder Perforation Post-TURBT: Definition, Incidence and Natural HistoryStudy(TURBT-BP) | unknown | N/A | 300 | Abdelwahab HashemOTHER | 1 | Oct 17, 2019 | clinicaltrials |
| NCT02665039 | A Trial With Vinflunine in Patients With Metastatic Bladder Cancer and Impaired Renal Function(VINGEM) | completed | Phase 2 | 62 | Dr Anders UllénOTHER | 2 | Oct 8, 2019 | clinicaltrials |
Data updated 23 days agoSource updated Oct 28, 2021source: clinicaltrials